Compare Magnolia Oil & Gas Corporation Class A Common Stock (MGY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Magnolia Oil & Gas Corporation Class A Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Magnolia Oil & Gas Corporation Class A Common Stock trades at $24.63 (market cap $6.69B), while Vertex Pharmaceuticals Incorporated trades at $513.01 (market cap $126.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 18.9× Magnolia Oil & Gas Corporation Class A Common Stock's market cap, and Magnolia Oil & Gas Corporation Class A Common Stock pays a 2.66% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Magnolia Oil & Gas Corporation Class A Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| MGY | VRTX | |
|---|---|---|
Market Cap | $6.69B | $126.35B |
Volume | 2,677,107 | 2,089,984 |
Sector | Energy | Health |
52-Week High | $32.36 | $557.96 |
52-Week Low | $21.24 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $6.80B | $120.48B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Magnolia Oil & Gas (MGY) trades at $25.11, up 2.66% with neutral technical signals. The company demonstrates strong fundamentals with a P/E of 10.97, net income margin of 28.77%, and consistent earnings beats. Recent WildFire Energy acquisition positions MGY for production doubling and significant free cash flow growth, with 2027 FCF projected over $1 billion. Analyst consensus remains strongly bullish with 66.7% buy ratings and $33.78 price target.
MGY presents compelling value with attractive valuation multiples and robust profitability metrics. The WildFire acquisition accelerates growth but introduces integration execution risk. Current price offers 35% upside to consensus target, though oil price volatility and operational execution remain key watchpoints for investors.
Vertex Pharmaceuticals (VRTX) trades at $485.22, down 4.3% amid bearish technical signals, though fundamentals remain strong with $12B revenue and 35% net margins. Recent positive Phase 2b data for kidney drug inaxaplin and dominant cystic fibrosis position support growth. Analyst consensus is bullish with $573.50 price target, but earnings misses in two of last three quarters highlight execution risks.
The outlook balances robust profitability and pipeline progress against competitive pressures and regulatory hurdles. Upside potential exists if new therapies gain approval, but volatility may persist near-term. Investors should weigh high valuations against the company's market leadership and expanding gene therapy portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Magnolia Oil & Gas Corporation Class A Common Stock
Magnolia Oil & Gas Corporation is an independent oil and gas exploration and production company operating in the Eagle Ford Shale and Austin Chalk formations of South Texas.
Read more on MGY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
